Group 1 - The company forecasts a net profit attributable to the parent company of between -80 million and -60 million yuan for the current period [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -150 million and -130 million yuan for the first half of 2025 [1] - The previous year's performance showed a total profit of -7.938 million yuan and a net profit attributable to the parent company of -18.8284 million yuan [1] Group 2 - The decline in performance is primarily due to a significant reduction in product orders from key customers, leading to a substantial decrease in operating revenue [1] - Insufficient capacity utilization due to reduced order income has resulted in high fixed costs and a decline in gross profit [1] - The company assures that there are no major uncertainties affecting the accuracy of this performance forecast beyond the mentioned factors [1]

证券代码：601718 证券简称：际华集团 公告编号：临 2025-036 际华集团股份有限公司 2025 年半年度业绩预告 重要内容提示： 1.本期业绩预告适用于"净利润为负值"的情形。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 3.本次业绩预告未经注册会计师审计。 2.际华集团股份有限公司（以下简称"公司""上市公司"）预计 2025 年半年度 实现归属于母公司所有者的净利润为-8,000 万元至-6,000 万元，预计 2025 年半年度 实现归属于母公司所有者扣除非经常性损益后的净利润为-15,000万元至-13,000 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 1.经公司财务部门初步测算，预计 2025 年半年度实现归属于母公司所有者的净利 润为-8,000 万元至-6,000 万元。 2. 预计 2025 年半年度实现归属于母公司所有者的扣除非经常性损益后的净利润 为-15,000 万元至-13,000 万元。 特此 ...

际华集团（601718）公告，预计2025年半年度实现归属于母公司所有者的净利润为-8000万元至-6000万 元，预计2025年半年度实现归属于母公司所有者扣除非经常性损益后的净利润为-1.5亿元至-1.3亿元。 主要原因是重点客户上半年产品订单减少，导致营业收入降幅较大；因订单收入减少带来的产能利用不 足，固定费用较高，毛利额下降影响了利润。 ...

Group 1 - The defense and military industry sector is experiencing adjustments, with the defense military ETF (512810) showing fluctuations, including a drop of over 1% before narrowing its losses [1] - The ETF has seen significant inflows, with over 1.68 billion yuan invested in the past 10 days, indicating strong bullish sentiment despite recent declines [1] - Among the 80 constituent stocks of the ETF, most have declined, with notable drops including Changcheng Military Industry down nearly 7% and Guorui Technology down over 3% [1] Group 2 - Analysts suggest that the upcoming mid-year report season may bring uncertainty regarding the performance of previously high-profile stocks, leading to potential short-term differentiation [3] - Huafu Securities maintains a bullish outlook on the sector, while Zhonghang Securities believes the defense military industry is in a state with ample upward potential and limited downside risk [3] - Zhejiang Merchants Securities highlights three main investment themes for the defense military sector by 2025: military trade, new domains and qualities, and restructuring [3] Group 3 - The defense military ETF (512810) has undergone a share split, reducing the trading threshold from approximately 120 yuan to around 60 yuan, making it more accessible for investors [4]

Group 1 - The brain-computer interface concept sector rose by 0.74%, ranking 8th among concept sectors, with 17 stocks increasing in value [1] - Leading gainers in the sector included Jihua Group, Entropy Technology, and Beiyikang, which rose by 7.59%, 5.92%, and 4.33% respectively [1] - The sector experienced a net inflow of 366 million yuan, with 18 stocks receiving net inflows, and 12 stocks seeing inflows exceeding 10 million yuan [1][2] Group 2 - Jihua Group had the highest net inflow of 331 million yuan, followed by Innovative Medical, Chengyitong, and Zhongke Information with net inflows of 162 million yuan, 77.97 million yuan, and 36.04 million yuan respectively [1][2] - The net inflow ratios for Jihua Group, Chengyitong, and Zhongke Information were 13.23%, 10.52%, and 8.87% respectively [2] - The trading volume and turnover rates for leading stocks in the sector were significant, with Jihua Group showing a turnover rate of 13.84% [2][3]

Group 1 - The stock of Jihua Group has experienced a significant increase, with 4 out of 6 trading days resulting in a trading limit up, leading to a cumulative increase of 29.63% and a turnover rate of 47.39% [2] - As of 9:50 AM, the stock's trading volume reached 322 million shares, with a transaction amount of 1.317 billion yuan, and a turnover rate of 7.33% [2] - The latest total market capitalization of the stock in A-shares is 18.445 billion yuan [2] Group 2 - The margin trading data shows that as of July 3, the stock's margin balance is 549 million yuan, with a financing balance of 547 million yuan, which increased by 30.35 million yuan from the previous trading day, reflecting a growth of 5.88% [2] - Over the past 6 days, the margin balance has cumulatively increased by 2.5167 million yuan, representing a growth of 0.46% [2] - The stock has appeared on the Dragon and Tiger list twice due to significant price deviations, with a cumulative deviation of 20% over three trading days and a daily deviation of 7% [2] Group 3 - The company's Q1 report indicates a total operating revenue of 1.631 billion yuan, a year-on-year decrease of 37.35%, while net profit reached 7.3961 million yuan, showing a year-on-year increase of 128.02% [2] - Recent stock performance data shows fluctuations in daily price changes and turnover rates, with notable increases on June 27 (9.88%) and June 30 (10.11%) [2] - The stock has seen significant net inflows from major funds, with a net buy of 71.1948 million yuan from the Shanghai Stock Connect [2]

Group 1 - The brain-computer interface (BCI) sector has seen significant advancements since 2025, with related stocks experiencing substantial increases, such as Saily Medical up 165.37% and Innovative Medical up 92.46% as of July 3 [1] - The A-share BCI sector has an overall increase of 49.1% this year, indicating a strong market sentiment towards this industry [1] - Policy support has been a driving force, with cities like Beijing and Shanghai launching five-year action plans for BCI development, aiming to cultivate innovative enterprises and achieve clinical application of BCI products by 2030 [1][2] Group 2 - The establishment of China's first BCI industrial cluster in Shanghai marks a significant step in the domestic BCI landscape, with the new facility expected to be operational within the year [2] - The stock market has reacted positively, with multiple BCI-related stocks experiencing consecutive gains, such as Saily Medical and Jihua Group achieving three consecutive trading limits [2] - The BCI theme index in A-shares has risen by 4.96% over the past month, reflecting ongoing investor interest [2] Group 3 - Companies are increasingly engaging with investors regarding BCI developments, with Chengyitong announcing a dual-track strategy in invasive and non-invasive BCI technologies [3] - Chengyitong plans to release three prototypes of neuro-rehabilitation devices integrating BCI technology by July 2024 [3] - Other companies, such as Chengdu Huamei and Pulite, are also exploring BCI applications, focusing on signal processing hardware and high-performance materials, respectively [3]

证券代码：601718 证券简称：际华集团 公告编号：临 2025-035 际华集团股份有限公司 关于股份回购进展公告 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购股份期间，上市公司应当每个月的前 3 个 交易日内，公告截至上月末的回购进展情况。现将公司股份回购的进展情况公告 如下： 截至 2025 年 6 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式回购股份数量 15,240,401 股，占公司当前总股本的比例为 0.3470%，回购成 交的最高价为人民币 2.73 元/股，最低价为人民币 2.51 元/股，已支付的总金额 为人民币 39,935,045.57 元（不含交易费用）。股份回购符合法律法规的有关规定 和公司回购股份方案的要求。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特 ...

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

Market Performance - The brain-computer interface concept declined by 2.60%, ranking among the top declines in concept sectors [1][2] - Within the sector, companies such as Xiangyu Medical and Aipeng Medical experienced significant declines, while Lepu Medical and ST Huaton saw increases of 4.05% and 3.05% respectively [1][3] Capital Flow - The brain-computer interface sector experienced a net outflow of 2.376 billion yuan, with 27 stocks seeing net outflows and 5 stocks exceeding 100 million yuan in outflows [2] - The company with the highest net outflow was Jihua Group, with a net outflow of 998.798 million yuan, followed by Innovation Medical and Haige Communication with net outflows of 288.118 million yuan and 186.919 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the brain-computer interface sector included Lepu Medical with a gain of 4.05% and ST Huaton with a gain of 3.05% [1][3] - The top losers included Xiangyu Medical with a decline of 8.34% and Aipeng Medical with a decline of 6.17% [3]